Evidence map›Paper›PMID 32924209›Full record

ArticleThe Journal of physiology2020

Acute activation of bronchopulmonary vagal nociceptors by type I interferons.

Mayur J Patil, Fei Ru, Hui Sun, Jingya Wang, Roland R Kolbeck, Xinzhong Dong, Marian Kollarik, Brendan J Canning, Bradley J Undem

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Role of NaThe Journal of physiology · 2023
    Article
  6. Infectious and Inflammatory Pathways to Cough.Annual review of physiology · 2023
    Review
  7. Article
  8. KThe Journal of physiology · 2022
    Article
  9. Review
  10. Article
  11. Contribution of tetrodotoxin-sensitive, voltage-gated sodium channels (NaAmerican journal of physiology. Regulatory, integrative and comparative physiology · 2021
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Mayur J PatilThe Johns Hopkins School of Medicine Departments of Medicine, Baltimore, MD.
Fei RuThe Johns Hopkins School of Medicine Departments of Medicine, Baltimore, MD.
Hui SunThe Johns Hopkins School of Medicine Departments of Medicine, Baltimore, MD.
Jingya WangAstraZeneca BioPharmaceuticals R&D Gaithersburg, MD.
Roland R KolbeckAstraZeneca BioPharmaceuticals R&D Gaithersburg, MD.
Xinzhong DongThe Johns Hopkins School of Medicine Departments of Neuroscience, Baltimore, MD.
Marian KollarikThe Johns Hopkins School of Medicine Departments of Medicine, Baltimore, MD.
Brendan J CanningThe Johns Hopkins School of Medicine Departments of Medicine, Baltimore, MD.ORCID 0000-0003-4197-5560
Bradley J UndemThe Johns Hopkins School of Medicine Departments of Medicine, Baltimore, MD.ORCID 0000-0001-5299-9029
Johns Hopkins University · USAstraZeneca (Canada) · CA

Funding

Mechanisms of Inflammatory Activation of Vagal C-Fibers in the Respiratory TractR01HL137807 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI UNDEM, BRADLEY JOEL · 2017 to 2020
$1.6M
NHLBI NIH HHS R01 HL137807
6 · The paper itself

Abstract

key pointsType I interferon receptors are expressed by the majority of vagal C-fibre neurons innervating the respiratory tract Interferon alpha and beta acutely and directly activate vagal C-fibers in the airways. The interferon-induced activation of C-fibers occurs secondary to stimulation of type 1 interferon receptors Type 1 interferons may contribute to the symptoms as well as the spread of respiratory viral infections by causing coughing and other defensive reflexes associated with vagal C-fibre activation ABSTRACT: We evaluated the ability of type I interferons to acutely activate airway vagal afferent nerve terminals in mouse lungs. Using single cell RT-PCR of lung-specific vagal neurons we found that IFNAR1 and IFNAR2 were expressed in 70% of the TRPV1-positive neurons (a marker for vagal C-fibre neurons) and 44% of TRPV1-negative neurons. We employed an ex vivo vagal innervated mouse trachea-lung preparation to evaluate the effect of interferons in directly activating airway nerves. Utilizing 2-photon microscopy of the nodose ganglion neurons from Pirt-Cre;R26-GCaMP6s mice we found that applying IFNα or IFNβ to the lungs acutely activated the majority of vagal afferent nerve terminals. When the type 1 interferon receptor, IFNAR1, was blocked with a blocking antibody the response to IFNβ was largely inhibited. The type 2 interferon, IFNγ, also activated airway nerves and this was not inhibited by the IFNAR1 blocking antibody. The Janus kinase inhibitor GLPG0634 (1 μm) virtually abolished the nerve activation caused by IFNβ. Consistent with the activation of vagal afferent C-fibers, infusing IFNβ into the mouse trachea led to defensive breathing reflexes including apneas and gasping. These reflexes were prevented by pretreatment with an IFN type-1 receptor blocking antibody. Finally, using whole cell patch-clamp electrophysiology of lung-specific neurons we found that IFNβ (1000 U ml

Indexed as

Interferon Type INociceptorsAnimalsBronchiMiceNeurons, AfferentNodose GanglionVagus NerveInterferon Type I2-photonairway lung nerve terminalscoughIFN type I receptorsIFNαIFNβIFNγinterferonsvagal afferentsvagal C-fibers

Identifiers

PMID32924209
PMCPMC7772956
OpenAlexW3086063649

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.